Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild®)

Assessment Status Rapid review complete
Drug Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumerate)
Brand Stribild®
Indication For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.
Assessment Process
Rapid review commissioned 28/04/2013
Rapid review completed 17/05/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

06/12/2013 Following commercial discussions with Gilead, the HSE has approved hospital pricing of Stribild®